Jingtai Technology and UCB Forge Authorization Pact for Advanced AI Platform in Large Molecule Drug Discovery - AI

7 x 24 Track global technological trends

Hot Topic

Day

News Topic

Jingtai Technology and UCB Forge Authorization Pact for Advanced AI Platform in Large Molecule Drug Discovery

2025-01-10

Ailux Biologics, a subsidiary of Jingtai Technology, has forged a collaborative partnership with the multinational biopharmaceutical giant UCB. Under this agreement, UCB has secured a license to utilize Jingtai Technology's cutting-edge XtalFold™ AI platform dedicated to large molecule drug research and development. Leveraging AI algorithms, the XtalFold™ platform predicts protein structures, thereby expediting the drug R&D process. UCB emphasized that this collaboration will enhance its technological capabilities and bolster its expertise in developing antibody drugs.

Previous page：NVIDIA and MediaTek Unveil the Miniaturized AI Sup...

Next page：Maitek Technology and UBTECH Robotics Launch Suzho...

Return to List

Hot Reading

2 day ago

Nvidia's GB10 Superchip trails Apple's M3 and Qualcomm's Snapdragon X Elite in latest benchmarks

2 day ago

Huawei's Kirin X90 may be the company's "Apple Silicon" moment

2 day ago

Lenovo's in-house Arm chip could rival Qualcomm and MediaTek, spotted in Yoga Pad Pro 2-in-1 convertible

2 day ago

CoreWeave reportedly looks to raise $1.5B in debt as IPO disappoints